

PMID	First author	Title	Journal
24557436	Acevedo-Gadea C	Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination	International Journal of Gynecological Cancer
24947095	Advani SH	Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients	Indian J Cancer
25052451	Agarwal N	Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients Wit	Oncologist
24907635	Aglietta M	A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine i	Ann Oncol
24743052	Alrwas A	Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclit	Melanoma Research
24405565	Ando Y	Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japane	Cancer Science
24563479	Angevin E	A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclon	Clin Cancer Res
25482239	Ansell SM	PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma	N Eng J Med
24416138	Aparicio J	A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therap	Plos One
24606884	Aruga A	Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract canc	J Transl Med
24434430	Bauer S	Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gast	Br J Cancer
25149088	Becerra CR	A phase I dose-escalation study of MEDI-575, a PDGFR α monoclonal antibody, in adults with adv	Cancer Chemother Pharmacol
25142843	Bellmunt J	Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Trea	Oncologist
24819685	Bendell JC	Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 i	Cancer Chemother Pharmacol
24173543	Bendell JC	Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin	Clin Cancer Res
25411085	Bendell JC	Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single	Cancer
24691674	Bendell JC	Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as seco	Invest New Drugs
24368401	Besse B	A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-lin	Ann Oncol
24685058	Bitting RL	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Pat	Clinical Genitourinary Cancer
25327558	Blumenthal GM	A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors	Oncotarget
23665950	Boku N	Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic	Invest New Drugs
25290091	Brana I	A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination	Br J Cancer
24395457	Britten CD	Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patient	Invest New Drugs
25102375	Cabanillas ME	A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer	Thyroid
24942404	Calvo E	Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pem	Invest New Drugs
24627219	Chan S	A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin	Cancer Chemother Pharmacol
25577133	Chang TC	Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients	Cancer Chemother Pharmacol
25312684	Chawla SP	A Phase 1B/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma	Cancer
25393368	Chen EX	A Phase I study of cyclin-dependent kinaseinhibitor, AT7519, in patients with advancedcancer: N	Br J Cancer
25752751	Cheson BD	A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lympho	Br J Haematol
24346101	Chiappori A	Obatoclox mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in re	Journal of Thoracic Oncology
24711549	Chien AJ	Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Hum	J Clin Oncol
24452395	Chiorean EG	A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFR α) n	Cancer Chemother Pharmacol
25536954	Choy E	Phase 1 Study of Oral Abexinostat, a Histone Deacetylase Inhibitor, in Combination With Doxoru	Cancer
24108668	Ciunci CA	Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients wit	Cancer
24916770	Cleary JM	A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combinati	Invest New Drugs

24983373	Cohen SJ	Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres	B J Cancer
25270361	Cohn A	A phase I dose-escalation study to a predefined dose of a transforming growth factor- β 1 monoclonal antibody	International journal of oncology
25403209	Conlon KC	Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine release	J Clin Oncol
24740268	Costello BA	Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors	Invest New Drugs
25542057	Coupe N	PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel	Eur J Cancer
24610297	Curtis KK	Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with prostate cancer	Cancer Chemother Pharmacol
25605849	Daud AI	Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination with Radiation	J Clin Oncol
25025963	Del Conte G	Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumors	Br J Cancer
24262587	Delord JP	Open-label, multicentre expansion cohort to evaluate imigatuzumab in pre-treated patients with advanced gastric cancer	Eur J Cancer
25059319	Doi T	Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors	Cancer Chemother Pharmacol
24297161	Dunbar EM	Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors	Invest New Drugs
24563480	Elez ME	First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors	Clin Cancer Res
24518092	Ellis PM	NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide	Journal of Thoracic Oncology
24714750	Eskens FA	A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel	Br J Cancer
25135998	Fanale MA	Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphoma	J Clin Oncol
25183650	Figg WD	A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with advanced solid tumors	Cancer Chemother Pharmacol
24615776	Flinn IW	Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treated patients with acute lymphoblastic leukemia	Blood
24141374	Floquet A	Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I study	Cancer Chemother Pharmacol
24306314	Fu S	Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced solid tumors	Invest New Drugs
25065668	Fumoleau P	A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 2005-10)	The Breast
25153538	Gadgeel SM	Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-positive NSCLC	Lancet Oncol
25023489	Galsky MD	Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus capecitabine	Cancer Chemother Pharmacol
24727324	Galsky MD	A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer	Clin Cancer Res
24323026	Gandhi L	Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer	J Clin Oncol
23756764	Ganesan P	Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer	Invest New Drugs
25891174	Garon EB	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer	N Eng J Med
24271274	Ghamande S	A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and efficacy of a novel agent	Invest New Drugs
24530971	Gopal AK	Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Stem Cell Transplantation	Biol Blood Marrow Transplant
24429877	Gray JE	A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, in combination with docetaxel	Clin Cancer Res
24438504	Hagihara A	Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion of irinotecan	Cancer Science
25615852	Hainsworth JD	Pazopanib and Liposomal Doxorubicin in the Treatment of Patients with Relapsed/Refractory Epithelial Ovarian Cancer	Cancer Investigation
25086465	Halperin DM	A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers	BMC Cancer
25533184	Hamberg P	Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel regimens	Cancer Chemother Pharmacol
24366297	Hamberg P	Pazopanib exposure decreases as a result of an ifosfamide-dependent drug drug interaction: results of a phase I study	Br J Cancer
24989332	Hassan R	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin	Cancer
24612787	Hazama S	A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic melanoma	Journal of Translational Medicine
25750312	Hecht JR	Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer	Anticancer Res

24456794	Hollebecque A	A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus	Eur J Cancer
24258465	Hong DS	A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleoprotein	Invest New Drugs
24746841	Hong DS	MABp1, a first-in-class true human antibody targeting interleukin-1 α in refractory cancers: an open-label	Lancet Oncol
24365125	Hong DS	A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Metastatic	Clinical Genitourinary Cancer
24752867	Hong DS	Dual Inhibition of the Vascular Endothelial Growth Factor Pathway: A Phase 1 Trial Evaluating Bevacizumab	Cancer
24807459	Horinouchi H	A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese	Cancer Chemother Pharmacol
24829073	Ikeda M	Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, a novel	Invest New Drugs
24521523	Ikeda M	Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular	Cancer Sci
24705975	Imbs DC	Pharmacokinetics of pazopanib administered in combination with bevacizumab	Cancer Chemother Pharmacol
24464355	Inada-Inoue M	Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors	Cancer Chemother Pharmacol
25262379	Infante JR	Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor	Eur J Cancer
25113756	Infante JR	Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients	J Clin Oncol
25057177	Inwards DJ	Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma	Ann Oncol
24283925	Isambert N	How to manage intravenous vinflunine in cancer patients with renal impairment: results of a phase I	Br J Clin Pharmacol
25687990	Ishiwatari H	Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary	Cancer Chemother Pharmacol
25202113	Iwahashi S	Effects of Valproic Acid in Combination with S-1 on Advanced Pancreatobiliary Tract Cancers: Clinical	Anticancer Res
25923549	Jänne PA	AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer	N Eng J Med
24496004	Jänne PA	Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination	J Thoracic Oncol
24242862	Jeong W	refractory solid tumors	Invest New Drugs
25287827	Johnson DB	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutated	J Clin Oncol
25029236	Joka M	Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy	Anti-Cancer Drugs
23959599	Jones JA	Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates	Am J Hematol
25486878	Kang YK	A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy	Cancer Chemother Pharmacol
24820348	Kashiwaba M	A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated with	Oncology
25427841	Kim KP	A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients	Oncology
25349975	Koczywas M	Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced	Br J Cancer
24337768	Komatsu Y	Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist	Invest New Drugs
25271537	Kumar A	A phase 1 dose-escalation study of XmAb 2513 in patients with relapsed or refractory Hodgkin lymphoma	Br J Haematol
24875132	Kurata T	Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel	Invest New Drugs
23979492	Lazar V	Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography	Invest New Drugs
24842883	Lee JM	Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian	J Natl Cancer Inst
25217393	Li C	Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil	Cancer Chemother Pharmacol
24755882	Lin CC	A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor	Br J Cancer
24708624	Linuma H	Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy	J Transl Med
24771350	Loriot Y	Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients	Invest New Drugs
23817974	LoRusso P	Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, a novel	Invest New Drugs
23903897	LoRusso PM	Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor	Invest New Drugs

24658629	Lv F	Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese p	Cancer Chemother Pharmacol
25355819	Maddocks K	A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and rel	Blood
24390424	Mahadevan D	Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in d	Cancer Chemother Pharmacol
25304209	Mahalingam D	Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patie	Cancer Chemother Pharmacol
24316557	Markowitz J	A Phase I trial of Bortezomib and Interferon Alfa-2B in Metastatic Melanoma	J Immunother
23801301	Martin-Liberal J	Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Sp	Invest New Drugs
25003665	Martin-Liberal J	Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine	Br J Cancer
25117615	Matsubara N	Phase-1 study of abiraterone acetate in chemotherapy-naive Japanese patients with castration-r	Cancer Sci
24663045	Mayer IA	Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide- 3-Kinase Inhibitor Buparlisib With L	J Clin Oncol
24819684	McRee AJ	A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus paniti	Cancer Chemother Pharmacol
25556030	Merchan JR	Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcino	Cancer Chemother Pharmacol
24338555	Misumi Y	A Feasibility Study of Carboplatin Plus Irinotecan Treatment for Elderly Patients with Extensive D	Jap J Clin oncol
24849582	Mita M	Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with	Cancer Chemother Pharmacol
23832397	Mita M	A phase I study of three different dosing schedules of the oral aurora kinase inhibitor MSC19923	Target Oncol
24842548	Mittal K	Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynam	Cancer biology and therapy
24387695	Molife LR	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotini	J Hematol Oncol.
24190702	Molina AM	A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in com	Cancer Chemother Pharmacol
24598448	Monk P	A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell	J Immunother
24618589	Morris JC	Phase I Study of GC1008 (Fresolimumab): A Human Anti- Transforming Growth Factor-Beta (TGF	Plos One
25012508	Mross K	Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorect	BMC Cancer
25202104	Murakami H	Phase I study of Efatutazone, an oral PPAR γ agonist, in patients with metastatic solid tumors.	Anticancer Res
24477603	Murakami H	An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vas	Cancer Chemother Pharmacol
23609829	Naing A	Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid t	Invest New Drugs
25143299	Nakai Y	A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic can	Cancer Chemother Pharmacol
25567350	Newman EM	A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inh	Cancer Chemother Pharmacol
24782485	Okusaka T	Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational full	Jpn J Clin Oncol
25052698	Olivier G	A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and pred	American J of Hematology
25146490	Pagel JM	Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relaps	Br J Haematol
24965340	Pan E	Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with br	J Neurooncol
23525756	Pant S	A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor,	Invest New Drugs
24633809	Patnaik A	A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in com	Cancer Chemother Pharmacol
24901237	Patnaik A	Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and n	Br J Cancer
25374407	Piatek CI	Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors	Cancer Chemother Pharmacol
24742900	Piha-Paul SA	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizum	Oncotarget
24674872	Plimack ER	A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinor	Oncologist
24875133	Plimack ER	abine with pegylated interferon α -2b in advanced melanoma: impact on DNA methylation and ly	Invest New Drugs
24880570	Plummer R	Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combinatio	Cancer Chemother Pharmacol

24908540	Powles T	A phase Ib study investigating the combination of everolimus and dovitinib in vascular endotheli	Eur J Cancer
24991839	Rangwala R	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced s	Autophagy
24991838	Rangwala R	Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus	Autophagy
23539344	Raymond E	A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combinati	Invest New Drugs
24322542	Reynés G	A phase I study of irinotecan in combination with metronomic temozolomide in patients with rel	Anticancer Drugs
25037139	Ribas A	Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated mel	Lancet Oncol
24132920	Ribrag V	A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administe	Clin Cancer Res
23645447	Richter S	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabi	Invest New Drugs
24914044	Rini B	A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or me	Ann Oncol
25034862	Robert C	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory ad	Lancet Oncol
24652201	Rodon J	Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inf	Invest New Drugs
24523439	Rodon J	A Phase I, Multicenter, Open-Label, First-in-Human, Dose- Escalation Study of the Oral Smoother	Clin Cancer Res
23568716	Rubinson DA	Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I stu	Invest New Drugs
24474568	Rudek MA	A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral the	Cancer
25103371	Saba NF	Phase 1 and Pharmacokinetic Study of Everolimus in Combination With Cetuximab and Carbopla	Cancer
24097863	Saif MW	A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administe	Clin Cancer Res
24744161	Salazar R	Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY233473	Cancer Chemother Pharmacol
24535315	Salazar R	Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors	
24692743	Sasaki Y	Phase I Study of Combination Therapy with Irinotecan, Leucovorin, and Bolus and Continuous-in	Anticancer Res
24480865	Sato D	Phase I study of nedaplatin prior to S-1 in patients with locally advanced head and neck squamo	Chemotherapy
24470511	Saura C	Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metas	Clin Cancer Res
24448638	Sausville E	Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with ge	Cancer Chemother Pharmacol
23860642	Schelman WR	A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors w	Invest New Drugs
25403217	Schultheis B	First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients V	J Clin Oncol
24166903	Shapiro GI	Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral par	Clin Cancer Res
25377157	Sharma S	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral pan	Cancer Chemother Pharmacol
24670165	Shaw AT	Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer	N Eng J Med
25264305	Shaw AT	Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer	N Eng J Med
25107918	Shimizu T	Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2	Clin Cancer Res
24585045	Shoji T	A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (T	Cancer Chemother Pharmacol
25253045	Slingerland M	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral pan	Cancer Chemother Pharmacol
24770667	Smith DA	Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2	Cancer Immunol Immunother
25327557	Soliman HH	A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in	Oncotarget
25193991	Soria JC	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lu	Ann Oncol
25434923	Spicer J	Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EG	Eur J Cancer
25625276	Spreafico A	A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in ad	Br J Cancer
24024696	Stein A	Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastr	Acta Oncol

24448640	Stewart CF	Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in	Cancer Chemother Pharmacol
24173967	Strickler JH	Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followe	Invest New Drugs
23733258	Strieth S	Phase I/II clinical study on safety and antivasular effects of paclitaxel encapsulated in cationic li	head neck
23553067	Sunakawa Y	Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharma	Invest New Drugs
25537627	Suzuki K	A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostat	Cancer Chemother Pharmacol
24634378	Tabernero J	A Pharmacodynamic/Pharmacokinetic Study of Ficlatazumab in Patients with Advanced Solid Tu	Clin Cancer Res
24688087	Takeoka H	Phase I Study of Carboplatin Combined with Pemetrexed for Elderly Patients with Advanced Non	Jap J Clin oncol
24800949	Tan AR	Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid	Br J Cancer
24779747	Terazawa T	Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatme	BMC Cancer
23589215	Tjulandin S	Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (er	Invest New Drugs
24674875	Toffalorio F	Phase Ib of Sorafenib in Combination With Everolimus in Patients With Advanced Solid Tumors, S	Oncologist
24440085	Tolcher A	A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tu	Eur J Cancer
25417902	Tolcher AW	Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib i	Cancer Chemother Pharmacol
24297683	Tolcher AW	A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patient	Cancer Chemother Pharmacol
24492162	Tsao AS	Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naïve patients with unrese	Clin Lung Cancer
24586081	Tsimberidou AM	Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer	J Natl Compr Canc Netw
23665866	Turkington RC	A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarb	Invest New Drugs
24696229	Ueda T	Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as	Invest New Drugs
25527204	Uronis HE	A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanc	Cancer Chemother Pharmacol
25422155	Uwagawa T	Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable bilia	Cancer Chemother Pharmacol
25125340	van Iersel LBJ	Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with me	Eur J Surg Oncol
25037684	Vergote I	A phase 1b, open-label study of trebananib combination with paclitaxel and carboplatin in pati	Eur J Cancer
25019569	Vergote I	A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotec	Gynecol Oncol
24894650	Vlahovic G	A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitax	Invest New Drugs
24458261	Von Mehren M	A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in sul	Invest New Drugs
24752449	Wakui H	A phase 1 and dose-finding study of LY2523355 (litrinesib), an Eg5 inhibitor, in Japanese patient	Cancer Chemother Pharmacol
24442032	Wakui H	Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targetin	Cancer Chemother Pharmacol
25617965	Wang J	Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-r	Clin Exp Metastasis
24916546	Wang-Gillam A	A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory	Cancer Chemother Pharmacol
24604265	Weekes CD	A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with adva	Invest New Drugs
25480557	Weihrauch MR	Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic soli	Eur J Cancer
24470557	Wen PY	North American Brain Tumor Consortium trial 04-02.	Neuro oncol
24435060	Wheler JJ	Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor	Cancer Chemother Pharmacol
25268371	Wilky BA	A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody,	B J Cancer
23532594	Yamada Y	A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gast	Gastric Cancer
25332421	Yamamoto H	Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-pos	Jap J Clin oncol
25034977	Yang J	Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity an	Cancer Chemother Pharmacol

23712440	Yoo C	Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as f	Invest New Drugs
25042202	Younes A	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and predni	Lancet Oncol
24612546	Zhang J	A phase I study of AST1306, a novel irreversibleEGFR and HER2 kinase inhibitor, in patients witha	Journal of Hematology & Oncology